Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy and preliminary experiences in 22 patients

作者全名："Jiang, Yu; Peng, Yueqiang; Ding, Siwei; Zheng, Yongbo; He, Yunfeng; Liu, Jiayu"

作者地址："[Jiang, Yu; Peng, Yueqiang; Ding, Siwei; Zheng, Yongbo; He, Yunfeng; Liu, Jiayu] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing, Peoples R China; [He, Yunfeng; Liu, Jiayu] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, 1st Youyi Rd, Chongqing, Peoples R China"

通信作者："He, YF; Liu, JY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, 1st Youyi Rd, Chongqing, Peoples R China."

来源：CANCER MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000899670400001

JCR分区：Q2

影响因子：2.9

年份：2023

卷号：12

期号：7

开始页：7835

结束页：7843

文献类型：Article

关键词：kidney-sparing; living quality; risk stratification; surgery; ureter cancer

摘要："Background: Several groups proved kidney-sparing surgery (KSS) had equivalent oncological outcomes compared with radical nephroureterectomy (RNU) for the low-risk upper urinary tract urothelial carcinoma (UTUC) patients. Whereas, the clinical efficacy of KSS for high-risk UTUC, especially for distal high-risk ureteral carcinoma, remains unclear. Objective: To evaluate the feasibility of KSS for patients with distal high-risk ureter cancer. Materials and methods: Our study included 22 patients who diagnose the distal high-risk ureter cancer and underwent KSS between May 2012 and July 2021 in the First Affiliated Hospital of Chongqing Medical University. Overall survival (OS), confirmed as the primary endpoint of present study, was assessed by a blinded independent review committee (BIRC). The secondary endpoints included the postoperative SF-36 (the short form 36 health survey questionnaire) score, progression-free survival (PFS), postoperative complications, and so on. Results: Overall, 17 (77.3%) and 5 (22.7%) patients underwent segmental ureterectomy (SU) and endoscopic ablation (EA), respectively. By the cut-off date, the mean OS was 76.3 months (95% CI: 51.3-101.1 months) and the mean PFS was 47.0 months (95% CI: 31.1-62.8 months), respectively. And the SF-36 score in a majority of patients was >300 (90.9%). Conclusion: This is a daring endeavor to explore the clinical efficacy of KSS in distal high-risk ureter cancer based on the high-risk UTUC criteria, which shows satisfactory results in the long-term prognosis and operation-associated outcomes. However, future randomized or prospective multicenter studies are necessary to validate our conclusions."

基金机构：　

基金资助正文：